chr2-25161223-T-C
Position:
Variant summary
Our verdict is Benign. Variant got -9 ACMG points: 0P and 9B. BP6BS1BS2
The NM_000939.4(POMC):āc.662A>Gā(p.Tyr221Cys) variant causes a missense change. The variant allele was found at a frequency of 0.00166 in 1,613,272 control chromosomes in the GnomAD database, including 7 homozygotes. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Genomes: š 0.00090 ( 0 hom., cov: 32)
Exomes š: 0.0017 ( 7 hom. )
Consequence
POMC
NM_000939.4 missense
NM_000939.4 missense
Scores
7
11
1
Clinical Significance
Conservation
PhyloP100: 5.64
Genes affected
POMC (HGNC:9201): (proopiomelanocortin) This gene encodes a preproprotein that undergoes extensive, tissue-specific, post-translational processing via cleavage by subtilisin-like enzymes known as prohormone convertases. There are eight potential cleavage sites within the preproprotein and, depending on tissue type and the available convertases, processing may yield as many as ten biologically active peptides involved in diverse cellular functions. The encoded protein is synthesized mainly in corticotroph cells of the anterior pituitary where four cleavage sites are used; adrenocorticotrophin, essential for normal steroidogenesis and the maintenance of normal adrenal weight, and lipotropin beta are the major end products. In other tissues, including the hypothalamus, placenta, and epithelium, all cleavage sites may be used, giving rise to peptides with roles in pain and energy homeostasis, melanocyte stimulation, and immune modulation. These include several distinct melanotropins, lipotropins, and endorphins that are contained within the adrenocorticotrophin and beta-lipotropin peptides. The antimicrobial melanotropin alpha peptide exhibits antibacterial and antifungal activity. Mutations in this gene have been associated with early onset obesity, adrenal insufficiency, and red hair pigmentation. Alternatively spliced transcript variants encoding the same protein have been described. [provided by RefSeq, Jan 2016]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Benign. Variant got -9 ACMG points.
BP6
Variant 2-25161223-T-C is Benign according to our data. Variant chr2-25161223-T-C is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 898576.We mark this variant Likely_benign, oryginal submissions are: {Likely_benign=1, Uncertain_significance=2}.
BS1
Variant frequency is greater than expected in population nfe. gnomad4 allele frequency = 0.0009 (137/152214) while in subpopulation NFE AF= 0.0016 (109/67998). AF 95% confidence interval is 0.00136. There are 0 homozygotes in gnomad4. There are 56 alleles in male gnomad4 subpopulation. Median coverage is 32. This position pass quality control queck.
BS2
High Homozygotes in GnomAdExome4 at 7 SD gene
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
POMC | NM_000939.4 | c.662A>G | p.Tyr221Cys | missense_variant | 3/3 | ENST00000395826.7 | NP_000930.1 | |
POMC | NM_001035256.3 | c.662A>G | p.Tyr221Cys | missense_variant | 4/4 | NP_001030333.1 | ||
POMC | NM_001319204.2 | c.662A>G | p.Tyr221Cys | missense_variant | 4/4 | NP_001306133.1 | ||
POMC | NM_001319205.2 | c.662A>G | p.Tyr221Cys | missense_variant | 3/3 | NP_001306134.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
POMC | ENST00000395826.7 | c.662A>G | p.Tyr221Cys | missense_variant | 3/3 | 2 | NM_000939.4 | ENSP00000379170 | P1 |
Frequencies
GnomAD3 genomes AF: 0.000907 AC: 138AN: 152096Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
138
AN:
152096
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000851 AC: 213AN: 250296Hom.: 0 AF XY: 0.000901 AC XY: 122AN XY: 135440
GnomAD3 exomes
AF:
AC:
213
AN:
250296
Hom.:
AF XY:
AC XY:
122
AN XY:
135440
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.00173 AC: 2533AN: 1461058Hom.: 7 Cov.: 32 AF XY: 0.00165 AC XY: 1197AN XY: 726834
GnomAD4 exome
AF:
AC:
2533
AN:
1461058
Hom.:
Cov.:
32
AF XY:
AC XY:
1197
AN XY:
726834
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.000900 AC: 137AN: 152214Hom.: 0 Cov.: 32 AF XY: 0.000752 AC XY: 56AN XY: 74420
GnomAD4 genome
AF:
AC:
137
AN:
152214
Hom.:
Cov.:
32
AF XY:
AC XY:
56
AN XY:
74420
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
TwinsUK
AF:
AC:
12
ALSPAC
AF:
AC:
17
ESP6500AA
AF:
AC:
2
ESP6500EA
AF:
AC:
15
ExAC
AF:
AC:
94
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Conflicting classifications of pathogenicity
Submissions summary: Uncertain:3Benign:1
Revision: criteria provided, conflicting classifications
LINK: link
Submissions by phenotype
POMC-related disorder Uncertain:1
Uncertain significance, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Aug 31, 2024 | The POMC c.662A>G variant is predicted to result in the amino acid substitution p.Tyr221Cys. This variant has been reported in the heterozygous state in several individuals with severe early-onset obesity (Lee et al. 2006. PubMed ID: 16459314; Kleinendorst et al. 2018. PubMed ID: 29970488). This variant segregated with obesity among five two-generation families; however, it was also detected in a control subject. Functional analysis in vitro indicated modest changes to protein structure and cell signaling properties (Lee et al. 2006. PubMed ID: 16459314). Another in vitro functional study showed suggestive evidence of loss of function (Table 3 and Supplemental Data Set, Shah et al. 2023. PubMed ID: 36864747). This variant is reported in 0.16% of alleles in individuals of European (Non-Finnish) descent in gnomAD. Although we suspect that this variant may be pathogenic, at this time its clinical significance remains uncertain due to absence of conclusive genetic and functional evidence. - |
Obesity Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Apr 27, 2017 | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). Publications were found based on this search. However, the evidence from the literature, in combination with allele frequency data from public databases where available, was not sufficient to rule this variant in or out of causing disease. Therefore, this variant is classified as a variant of unknown significance. - |
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | May 20, 2019 | Reported previously in published literature, sometimes using alternate nomenclature (Y5C), in association with obesity (Lee et al., 2006; Biebermann et al., 2006; Creemers et al., 2008; Dash et al., 2010; Nordang et al., 2017; Kleinendorst et al., 2018); Seen in multiple family members with obesity from several unrelated families in published literature, but some family members with obesity did not harbor this variant (Lee et al., 2006; Biebermann et al., 2006; Dash et al., 2010); Published functional studies suggest this variant is associated with altered three-dimensional structure of the beta-MSH peptide, reduced binding to MC4R, and decreased generation of cAMP (Lee et al., 2006); This variant is associated with the following publications: (PMID: 16459314, 18091355, 20349035, 18840502, 18697863, 28377240, 29970488, 16459315) - |
Obesity due to pro-opiomelanocortin deficiency Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Apr 27, 2017 | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). No publications were found based on this search. Allele frequency data from public databases allowed determination this variant is unlikely to cause disease. Therefore, this variant is classified as likely benign. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
BayesDel_addAF
Uncertain
T
BayesDel_noAF
Pathogenic
CADD
Uncertain
DANN
Uncertain
DEOGEN2
Uncertain
D;D;D;D;T
Eigen
Uncertain
Eigen_PC
Uncertain
FATHMM_MKL
Uncertain
D
LIST_S2
Pathogenic
D;.;.;.;D
M_CAP
Uncertain
D
MetaRNN
Uncertain
D;D;D;D;D
MetaSVM
Uncertain
D
MutationAssessor
Uncertain
M;M;M;M;.
MutationTaster
Benign
D;D;D;D
PrimateAI
Uncertain
T
PROVEAN
Pathogenic
D;D;D;D;D
REVEL
Pathogenic
Sift
Pathogenic
D;D;D;D;D
Sift4G
Pathogenic
D;D;D;D;.
Polyphen
D;D;D;D;.
Vest4
MVP
MPC
1.1
ClinPred
T
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at